Abbott Laboratories 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Shareholders held by Abbott Laboratories on April 29, 2016. The filing details the outcomes of shareholder votes regarding board elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Board of Directors Election: Shareholders elected the entire Board of Directors. All nominees received a majority of votes cast. Notable vote counts included:
- Robert J. Alpern, M.D.: 1,086,257,937 votes for; 9,089,950 withheld.
- Miles D. White: 1,044,270,331 votes for; 51,077,556 withheld.
- Glenn F. Tilton: 1,056,326,280 votes for; 39,021,607 withheld.
- Auditor Ratification: Shareholders ratified the appointment of Ernst & Young LLP. The vote was 1,292,626,550 for, 6,402,570 against, and 1,991,205 abstaining.
- Executive Compensation: Shareholders approved the compensation of named executive officers (advisory vote). 94.01% of votes cast were in favor. The vote was 1,029,769,849 for, 55,384,958 against, and 10,193,080 abstaining.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the final composition of the Board of Directors following the April 29, 2016 election.
- Confirm the continued engagement of Ernst & Young LLP as the independent auditor.
- Review the proxy statement for details on the specific executive compensation packages approved by 94.01% of voting shareholders.
- Note the significant number of broker non-votes (205,672,438) recorded for the director elections and executive compensation vote.